BIT
GYRE icon

BlackRock Institutional Trust’s Gyre Therapeutics GYRE Stock Holding History

BlackRock Institutional Trust’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$92K Sell
1,256
-109
-8% -$9.8K ﹤0.01% 3662
2016
Q3 		$186K Sell
1,365
-70
-5% -$10.6K ﹤0.01% 3617
2016
Q2 		$245K Sell
1,435
-6
-0.4% -$1.02K ﹤0.01% 3609
2016
Q1 		$272K Sell
1,441
-28
-2% -$6.75K ﹤0.01% 3570
2015
Q4 		$517K Hold
1,469
– – ﹤0.01% 3502
2015
Q3 		$770K Buy
1,469
+4
+0.3% +$6.1K ﹤0.01% 3408
2015
Q2 		$3.22M Buy
1,465
+12
+0.8% +$24.1K ﹤0.01% 2927
2015
Q1 		$3.4M Buy
1,453
+1
+0.1% +$2.07K ﹤0.01% 2893
2014
Q4 		$3.01M Buy
1,452
+15
+1% +$28.9K ﹤0.01% 2938
2014
Q3 		$2.86M Buy
1,437
+138
+11% +$341K ﹤0.01% 2913
2014
Q2 		$4.62M Sell
1,299
-393
-23% -$1.28M ﹤0.01% 2818
2014
Q1 		$6.33M Sell
1,692
-236
-12% -$874K ﹤0.01% 2682
2013
Q4 		$6.3M Buy
1,928
+381
+25% +$1.5M ﹤0.01% 2678
2013
Q3 		$6.47M Buy
1,547
+135
+10% +$543K ﹤0.01% 2601
2013
Q2 		$4.75M Buy
+1,412
New +$5.37M ﹤0.01% 2726

Other funds holding GYRE

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return
CCM
Colorado Capital Management Boulder, Colorado $293M AUM 22.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

BlackRock Institutional Trust's GYRE Position: Q4 2016 in Review

BlackRock Institutional Trust reduced its Gyre Therapeutics (GYRE) stake by 8% in Q4 2016, selling an estimated $9.8K and leaving 1,256 shares worth $92K. The position accounts for ﹤0.01% of the portfolio, ranked #3662.

BlackRock Institutional Trust first reported a position in GYRE in Q2 2013 and has held it in 15 quarters since. The position peaked at $6.47M in Q3 2013. 27 funds tracked by Wall St. Rank hold GYRE as of Q4 2016.

  • BlackRock Institutional Trust held 1,256 shares of Gyre Therapeutics worth $92K as of Q4 2016.
  • BlackRock Institutional Trust sold 109 Gyre Therapeutics shares in Q4 2016, an estimated $9.8K.
  • Gyre Therapeutics made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #3662 holding.
  • BlackRock Institutional Trust first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Institutional Trust's Gyre Therapeutics position peaked at $6.47M in Q3 2013.
  • 27 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.